Deutsche Bank
MTNB icon

Deutsche Bank’s Matinas BioPharma MTNB Stock Holding History

Deutsche Bank’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,059
Closed -$275K – 5429
2019
Q1 		$275K Buy
+5,059
New +$272K ﹤0.01% 3811
2018
Q4 		– Sell
-215
Closed -$10K – 5320
2018
Q3 		$10K Sell
215
-1,035
-83% -$22.2K ﹤0.01% 5078
2018
Q2 		$27K Sell
1,250
-541
-30% -$15.6K ﹤0.01% 4947
2018
Q1 		$68K Sell
1,791
-1,170
-40% -$61.9K ﹤0.01% 4649
2017
Q4 		$171K Buy
2,961
+1,921
+185% +$124K ﹤0.01% 4096
2017
Q3 		$67K Sell
1,040
-165
-14% -$11K ﹤0.01% 4289
2017
Q2 		$101K Buy
+1,205
New +$162K ﹤0.01% 4196

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Deutsche Bank's MTNB Position: Q2 2019 in Review

Deutsche Bank sold out of Matinas BioPharma (MTNB) in Q2 2019, closing a stake of 5,059 shares — an estimated $275K sold.

Deutsche Bank first reported a position in MTNB in Q2 2017 and held it in 7 quarters. The position peaked at $275K in Q1 2019. 47 funds tracked by Wall St. Rank hold MTNB as of Q2 2019.

  • Deutsche Bank reported no remaining Matinas BioPharma position as of Q2 2019 after selling out during the quarter.
  • Deutsche Bank sold 5,059 Matinas BioPharma shares in Q2 2019, an estimated $275K.
  • Deutsche Bank first reported a position in Matinas BioPharma in Q2 2017 and held it in 7 quarters.
  • Deutsche Bank's Matinas BioPharma position peaked at $275K in Q1 2019.
  • 47 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2019.

Based on Deutsche Bank's 13F filing for Q2 2019, filed 14 Aug 2019.